(Q46984013)

English

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

scientific article published in September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

phase II clinical trial

0 references

0 references

author name string

M Knowling

1

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

M Blackstein

2

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

R Tozer

3

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

V Bramwell

4

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

J Dancey

5

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

N Dore

6

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

S Matthews

7

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

E Eisenhauer

8

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

number of pages

5

1 reference

based on heuristic

inferred from page(s)

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

24

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

5

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

435-439

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

https://scigraph.springernature.com/pub.10.1007/s10637-006-6406-7

0 references

Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinomial phase II cancer trials incorporating response and early progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uneven distribution of protein kinase C-alpha and -beta isozymes in human sarcomas and carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of protein kinase-C-isoenzymes in human tumor cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinomial phase II trial designs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-intensive chemotherapy in advanced adult soft tissue sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16528479

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-006-6406-7

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16528479

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46984013&oldid=2140895422"